Plaintiff’s Seminar Held for Granuflo Class Action
Michelle A. Parfitt joined a handful of lawyers from across the country at a seminar for plaintiffs pursuing an action against the manufacturers of GranuFlo, a drug administered to patients prior to dialysis. The discussion, hosted by the legal advocacy group American Association for Justice, took place on December 6, 2012 in New York City.
According to the U.S. Food and Drug Administration (FDA), the makers of the drug, Fresenius, knew as early as 2010 that the drug increased risks of cardiac arrest in patients. Yet they failed to warn patients of this deadly side effect until earlier this year. On March 29, 2012, the FDA issued a Class 1 Recall for Granuflo, the most serious type of recall.
Over 940 deaths have been linked to the use of Granuflo, and many lawsuits have since been filed against Fresenius. Ms. Parfitt spoke with plaintiffs about the ongoing case, including process, strategy, and theories of liability. By speaking directly with all those involved, we hope to promote more dialog and swifter resolution of these important cases.